Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG) (D-FOG)
Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment. Feasibility and Acceptability Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Evaluation of the feasibility of a new geriatric fragility screening tool (D-FOG) in patients aged ≥ 75 years during oncological treatment:
- Number of D-FOGs filled in: comparison with the number of patients included in the study and the number of visits of each patient.
- Regularity of the D-FOG self-questionnaire by the patient: comparison with the number of visits of the patient for a chemotherapy cure (HDJ or HDS).
- Number of criteria entered by D-FOG: comparison with the total number of criteria to be filled in
- Criterion analysis of D-FOG
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Poitiers, France, 86000
- CHU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 75 years and over
- Carriers of diagnosed cancer (excluding hematology)
- Whatever the location, uniqueness or multiple, duration of development and treatment status (adjuvant, neoadjuvant, locally advanced or metastatic)
- Seen in nursing consultant
- Beginning an oncological treatment
- Supported for oncology day hospital (HDJ) or weekly (HDS) chemotherapy
- Patient not opposed to participate in the study
Exclusion Criteria:
- Patients under 75 years of age
- Having not had an IDE ad consultation
- During oncological treatment
- Receiving Oral Therapy or hormone therapy alone
- Treated by radiotherapy alone or surgery alone
- Not attending a day or week oncology hospital
- Refusal to participate in research
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group D-FOG
Filling of a self-questionnaire before each chemotherapy cure
|
Filling of a self-questionnaire before each chemotherapy cure
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the feasibility of a new geriatric fragility screening tool (D-FOG) in patients aged ≥ 75 years during oncological treatment.
Time Frame: 3 months
|
Feasibility of D-FOG for patients : number of D-FOGs filled in, regularity of the D-FOG self-questionnaire by the patient, number of criteria entered by D-FOG, criterion analysis of D-FOG
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: VALERO SV SIMON, Doctor, CHU Poitiers
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 2017-A02188-45
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
NCT05693831RecruitingCancer | Relapsed Cancer | Refractory Cancer
-
NCT02045381CompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer Pelvis
-
NCT07196241RecruitingCancer | Adolescent Cancer | Young Adult Cancer
-
NCT04310345CompletedAdvanced Cancer | Relapsed Cancer | Refractory Cancer
-
NCT02511821CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer
-
NCT04044430TerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer
-
NCT07224204RecruitingCancer | Adolescent Cancer | Young Adult Cancer
-
NCT05259696CompletedMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer
-
NCT03146039WithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III
-
NCT05633342RecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver Cancer
Clinical Trials on Self-questionnaire
-
NCT06630182Recruiting
-
NCT03661203Unknown
-
NCT07186335Not yet recruiting
-
NCT06376799RecruitingPatient Preference | Advance Care Planning
-
NCT05000333Completed
-
NCT03013283CompletedInterface, Mask | Continuous Positive Airway Pressure (CPAP) | Non Invasive Ventilation (NIV) | Hyperventilation Anxiety | Sleep Apnea Syndrome (OSAS)
-
NCT07485660Not yet recruiting
-
NCT04846595Completed
-
NCT03075917Recruiting
-
NCT05327634Completed